Answers are grounded in this paper and cite their sources.
Low muscle mass (LMM) is associated with poor outcomes in cancer, but its role in cancer development remains unclear. We examined pre-existing LMM and site-specific cancer incidence. We analyzed 4,441,403 adults who underwent national health screening in 2012. LMM was defined as the lowest sex-specific quartile of the predicted appendicular skeletal muscle mass index (ASMI). Cox models were used in men and women (<50 and ≥50 years), adjusting for demographic and clinical factors and body mass index (BMI). ASMI was additionally modeled continuously using alternative adjustments for BMI, non-ASM mass index, and predicted fat mass index. After adjustment, men with LMM showed minimally increased overall cancer risk (hazard ratio [HR] 1.04, 95% CI 1.02-1.06), with elevated risks for esophageal, liver, and lung cancers (HRs 1.08-1.22) and decreased risks for prostate, renal, and thyroid cancers (HRs 0.86-0.87). Women aged <50 years showed slightly reduced overall cancer risk (HR 0.95, 95% CI 0.92-0.97), whereas women aged ≥50 years showed no overall association (HR 0.98, 95% CI 0.96-1.01) but inverse associations for colon, pancreatic, breast, renal, and thyroid cancers. Findings were generally similar using AWGS 2019 criteria and a three-year lag. However, predicted ASMI was highly correlated with other body-composition measures, particularly in women, limiting interpretation of mutually adjusted continuous estimates. LMM alone was not strongly associated with increased cancer risk. Predicted muscle mass and cancer risk should be interpreted in the context of overall body composition.
No takes yet. Share an insight, caveat, or question.
Chun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: